Gracell Biotechnologies Inc is a global clinical-stage biopharmaceutical company. The company specializes in developing cell therapies for the treatment of cancer and autoimmune diseases, utilizing allogeneic and autologous platforms to produce CAR-T cell therapies. Gracell has developed FasTCAR and TruUCAR technology platforms and a SMART CARTTM technology module. They have also developed a 2nd generation enhanced CAR-T molecule for treating solid tumors and have been granted FDA Orphan Drug Designation for their BCMA/CD19 dual-targeting CAR-T cell therapy candidate GC012F for the treatment of multiple myeloma. Gracell has also dosed the first patients in a First-in-Human clinical trial evaluating GC012F for the treatment of B-Cell Non-Hodgkin's Lymphoma.
总部
Building 12, Block B, Phase Ii, Biobay Industrial Park, 218 Sangtian Street, Suzhou Industrial Park
苏州; 江苏;
邮编: 215123
联系方式: 购买Gracell Biotechnologies Inc.报告以查看信息。
EMIS公司简介是一个更大的信息服务的一部分，它结合了公司，行业和国家数据和分析在超过125个新兴市场.
请求EMIS服务的演示查看更多信息, 申请试用